bluebird bio (BLUE) News Today $8.50 -0.73 (-7.91%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period StockNews.com Initiates Coverage on bluebird bio (NASDAQ:BLUE)StockNews.com started coverage on bluebird bio in a research report on Friday. They issued a "sell" rating on the stock.December 20 at 2:47 AM | marketbeat.comMarch Biosciences Elects Peter Olagunju as Chair of Board of DirectorsDecember 19 at 11:38 AM | markets.businessinsider.combluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Rating of "Hold" from Brokeragesbluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) has earned a consensus rating of "Hold" from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, six have issued a hold recommendationDecember 18 at 4:26 AM | marketbeat.combluebird bio (NASDAQ:BLUE) Shares Up 15.3% - Time to Buy?bluebird bio (NASDAQ:BLUE) Trading Up 15.3% - Should You Buy?December 16, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Trading Down 13.4% - Should You Sell?December 15, 2024 | americanbankingnews.combluebird bio (NASDAQ:BLUE) Stock Price Down 13.4% - Time to Sell?bluebird bio (NASDAQ:BLUE) Stock Price Down 13.4% - Should You Sell?December 13, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comStockNews.com began coverage on bluebird bio in a research report on Thursday. They set a "sell" rating for the company.December 12, 2024 | marketbeat.combluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and ExpositionDecember 8, 2024 | businesswire.comBluebird Bio participates in CMMI Cell and Gene Therapy Access ModelDecember 5, 2024 | markets.businessinsider.comMakers of Sickle Cell Disease Gene Therapy to Participate in Payment Model, CMS SaysDecember 5, 2024 | msn.comCMS enters agreement with Vertex, bluebird to improve access to gene therapiesDecember 4, 2024 | msn.combluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access ModelDecember 4, 2024 | businesswire.combluebird bio (NASDAQ:BLUE) Coverage Initiated at StockNews.comStockNews.com began coverage on shares of bluebird bio in a report on Wednesday. They issued a "sell" rating on the stock.December 4, 2024 | marketbeat.comFDA investigating safety risks of bluebird's SkysonaNovember 27, 2024 | msn.comFDA investigating safety risks of bluebird's SkysonaNovember 27, 2024 | msn.comFDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory actionNovember 27, 2024 | msn.comFDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory actionNovember 27, 2024 | msn.comFDA investigates risk of blood cancers from bluebird bio's gene therapyNovember 27, 2024 | reuters.combluebird bio (NASDAQ:BLUE) Now Covered by StockNews.comStockNews.com initiated coverage on shares of bluebird bio in a research report on Tuesday. They issued a "sell" rating for the company.November 26, 2024 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of "Hold" by BrokeragesShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned a consensus rating of "Hold" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a hNovember 23, 2024 | marketbeat.comBluebird Bio: Hold Rating Amid Positive Patient Starts and Financing ChallengesNovember 19, 2024 | markets.businessinsider.comB of A Securities Downgrades bluebird bio (BLUE)November 17, 2024 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.combluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...November 15, 2024 | finance.yahoo.combluebird bio extends selloff as BofA and J.P. Morgan cut after Q3 resultsNovember 15, 2024 | msn.comBluebird Bio price target lowered to $2 from $4 at BarclaysNovember 15, 2024 | markets.businessinsider.comBluebird Bio downgraded to Neutral at BofA on slower expected Lyfgenia rampNovember 15, 2024 | markets.businessinsider.comJP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding OptionsNovember 15, 2024 | benzinga.comRoyal Bank of Canada Reaffirms "Sector Perform" Rating for bluebird bio (NASDAQ:BLUE)Royal Bank of Canada reiterated a "sector perform" rating and issued a $4.00 target price on shares of bluebird bio in a research note on Friday.November 15, 2024 | marketbeat.combluebird bio downgraded by Bank of America, shares tumbleNovember 15, 2024 | proactiveinvestors.combluebird bio (NASDAQ:BLUE) Price Target Lowered to $2.00 at BarclaysBarclays lowered their target price on shares of bluebird bio from $4.00 to $2.00 and set an "overweight" rating for the company in a research note on Friday.November 15, 2024 | marketbeat.comJPMorgan Chase & Co. Downgrades bluebird bio (NASDAQ:BLUE) to UnderweightJPMorgan Chase & Co. downgraded shares of bluebird bio from a "neutral" rating to an "underweight" rating in a research note on Friday.November 15, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Downgraded to "Neutral" Rating by Bank of AmericaBank of America cut shares of bluebird bio from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $3.00 to $0.50 in a research note on Friday.November 15, 2024 | marketbeat.comExploring bluebird bio's Earnings ExpectationsNovember 13, 2024 | benzinga.comBluebird Bio’s Key Decisions and Shareholder Engagement in 2024November 7, 2024 | markets.businessinsider.combluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results CallNovember 7, 2024 | finance.yahoo.combluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved TherapiesOctober 31, 2024 | msn.combluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Recommendation of "Hold" from AnalystsShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have received an average recommendation of "Hold" from the twelve brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating aOctober 29, 2024 | marketbeat.combluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.comStockNews.com started coverage on shares of bluebird bio in a report on Friday. They issued a "sell" rating on the stock.October 25, 2024 | marketbeat.comLife Without Sickle Cell Beckons Boy Who Completed Gene TherapyOctober 22, 2024 | nytimes.comMillennium Management LLC Sells 1,092,888 Shares of bluebird bio, Inc. (NASDAQ:BLUE)Millennium Management LLC reduced its position in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 17.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,146,653 shares of the biotechnology company's stocOctober 12, 2024 | marketbeat.comLentiviral Gene Therapy Beneficial for Early Cerebral AdrenoleukodystrophyOctober 11, 2024 | msn.comMaintaining Hold on Bluebird Bio Amid Skysona Safety Concerns and Financial ConstraintsOctober 11, 2024 | markets.businessinsider.com7 children given bluebird's Skysona developed blood cancer: studyOctober 11, 2024 | msn.comBluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trialsOctober 11, 2024 | msn.comBluebird Bio (BLUE) Stock Dips Amid Market VolatilityOctober 8, 2024 | gurufocus.comRenaissance Technologies LLC Sells 1,396,196 Shares of bluebird bio, Inc. (NASDAQ:BLUE)Renaissance Technologies LLC cut its stake in shares of bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 63.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 791,504 shares of the biotechnology company'sOctober 8, 2024 | marketbeat.combluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 4, 2024 | businesswire.comBluebird Bio (BLUE) Stock Surges 5.04% Amid Market MovementsOctober 2, 2024 | gurufocus.comBluebird Bio’s Restructuring Efforts and Financial Outlook: A Cautious Hold RatingSeptember 28, 2024 | markets.businessinsider.com Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.100.60▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼55▲BLUE Articles Average Week Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Krystal Biotech News Today Arcellx News Today ADMA Biologics News Today Immunovant News Today Scholar Rock News Today CRISPR Therapeutics News Today Denali Therapeutics News Today Twist Bioscience News Today Vericel News Today SpringWorks Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLUE Stock Alerts